Philip Morris International, one of the largest tobacco companies in the world, has undergone a dramatic transformation over the past few years. As cigarette smoking continues its decades-long decline, PMI has aggressively expanded into smokeless alternatives, with Zyn – its flagship nicotine pouch brand – emerging as a major driver of growth.
Zyn's rapid adoption in the U.S. market has played a key role in PMI's resurgence. Earlier this year, the Food and Drug Administration (FDA) authorized 20 Zyn products for sale, determining that these pouches contain "substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products." This regulatory green light reinforced Zyn's positioning as a lower-risk alternative to traditional tobacco products.
